Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574717 | PMC |
| http://dx.doi.org/10.1001/jamainternmed.2024.6149 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Next-Generation Multitarget Stool DNA vs Fecal Immunochemical Test in Colorectal Cancer Screening.
JAMA Intern Med
November 2024
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Biomarkers in Colorectal Cancer: Actual and Future Perspectives.
Int J Mol Sci
October 2024
Discipline of Oncological Radiotherapy and Medical Imaging, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Biomarkers in colorectal cancer (CRC) are of great interest in the current literature due to improvements in techniques such as liquid biopsy and next-generation sequencing (NGS). However, screening methods vary globally, with multi-target stool DNA (mt-sDNA) predominantly used in the USA and, more recently, the Cologuard Plus; biomarkers such as the Galectins family and septins show promise in early detection. Gut microbiome assessments, such as Fusobacterium nucleatum, are under intense exploration.
View Article and Find Full Text PDFProjected Impact and Cost-Effectiveness of Novel Molecular Blood-Based or Stool-Based Screening Tests for Colorectal Cancer.
Ann Intern Med
December 2024
Division of Gastroenterology and Hepatology, Oregon Health and Sciences University, Portland, Oregon (D.L.).
Background: Cell-free DNA blood tests (cf-bDNA) and next-generation stool tests could change colorectal cancer (CRC) screening.
Objective: To estimate the clinical and economic impacts of novel CRC screening tests.
Design: Cost-effectiveness analysis using MOSAIC (Model of Screening and Surveillance for Colorectal Cancer).
Case report: a case of lung squamous cell carcinoma with a novel FGFR3-IER5L fusion mutation responding to anlotinib.
Front Oncol
October 2024
Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Article Synopsis
- * A patient with LUSC was found to have a new FGFR3-IER5L fusion through next generation sequencing and opted for anlotinib treatment instead of conventional therapies like surgery or chemotherapy.
- * Anlotinib, a multi-target tyrosine kinase inhibitor, led to a partial response in the patient, resulting in a progression-free survival of 3.8 months.
Fritillaria steroidal alkaloids and their multi-target therapeutic mechanisms: insights from network pharmacology.
Naunyn Schmiedebergs Arch Pharmacol
October 2024
CSIR-Institute of Himalayan Bioresource Technology, Palampur, 176061, Himachal Pradesh, India.
Medicinal Fritillaria herbs, known for their rich content of steroidal alkaloids, have emerged as promising candidates in the treatment of chronic diseases due to their diverse pharmacological properties. Leveraging advancements in network pharmacology and molecular docking, this study explores the multi-target mechanisms through which these alkaloids exert therapeutic effects. The integration of bioinformatics, systems biology, and pharmacology in drug discovery has provided insights into the molecular interactions and pathways influenced by Fritillaria steroidal alkaloids.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!